This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Lexaria Bioscience's Median PS Value or its related term are showing as below:
LEXX'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.48 Med: 0.78 Max: 0.95
Current: 0.48
During the past 13 years, the highest Price to Median PS Value of Lexaria Bioscience was 0.95. The lowest was 0.48. And the median was 0.78.
LEXX's Price-to-Median-PS-Value is ranked better than 65.89% of 258
companies
in the Biotechnology industry
Industry Median: 0.68
vs LEXX: 0.48
Lexaria Bioscience Median PS Value Historical Data
The historical data trend for Lexaria Bioscience's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lexaria Bioscience's Median PS Value
For the Biotechnology subindustry, Lexaria Bioscience's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexaria Bioscience's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 99.1429.
Lexaria Bioscience's Revenue per Share for the trailing twelve months (TTM) ended in Nov. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.035.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexaria Bioscience (NAS:LEXX) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Lexaria Bioscience's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
1.67
/
3.47
=
0.48
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexaria Bioscience Median PS Value Related Terms
Thank you for viewing the detailed overview of Lexaria Bioscience's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LEXX has been successfully added to your 